ArticleNano today2011
Toxicology and clinical potential of nanoparticles.
Article in Nano today, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
144 citing papers in PubMed.
- Nanoparticles for antiviral nucleotide analogs: approaches and analytical challenges.Journal of virology · 2026Review
- Nanotechnology revolutionizing antimicrobial therapy for superbug infections.Discover nano · 2026Review
- Drug Polymer Nanoparticles: An Advancement in Biomedical Solutions and Targeted Drug Delivery.Drug design, development and therapy · 2026Review
- Promoting Drp1-Mediated Mitochondrial Division in Nickel Nanoparticles-Induced Reproductive Toxicity in GC-2 Cells.Nanomaterials (Basel, Switzerland) · 2025Article
- Nanobiosensors for revolutionizing parasitic infections diagnosis: a critical review to improve global health with an update on future challenges prospect.European journal of medical research · 2025Review
- Nanostructured Lipoxin A4: Understanding Its Biological Behavior and Impact on Alzheimer's Disease (Proof of Concept).Pharmaceutics · 2025Article
- Functionalized Cerium Oxide Nanoparticles Enhance Penetration into Melanoma Spheroids In Vivo through Angiogenesis.Advanced healthcare materials · 2025Article
- Size-dependent interactions between calciprotein particles and vascular endothelium.Materials today. Bio · 2025Article
- Current and Near-Future Technologies to Quantify Nanoparticle Therapeutic Loading Efficiency and Surface Coating Efficiency with Targeted Moieties.Bioengineering (Basel, Switzerland) · 2025Review
- Bone-derived nanoparticles (BNPs) enhance osteogenic differentiationNanoscale advances · 2025Article
- Nanoparticle tools for maximizing oral drug delivery.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025Review
- Protein-Based Silver Nanoparticles: Synthesis, Characterization, Administration, and Nanomedicine Applications.International journal of biomaterials · 2025Review
- Lipid-core nanocapsules containing simvastatin do not affect the biochemical and hematological indicators of toxicity in rats.Toxicology research · 2024Article
- Effects of Resveratrol on Nonmelanoma Skin Cancer (NMSC): A Comprehensive Review.Food science & nutrition · 2024Review
- Double safety guarantees: Food-grade photothermal complex with a pH-triggered NIR absorption from zero to one.Fundamental research · 2024Article
- Synthesis and synergistic antibacterial efficiency of chitosan-copper oxide nanocomposites.Heliyon · 2024Article
- Nanomaterials in Immunology: Bridging Innovative Approaches in Immune Modulation, Diagnostics, and Therapy.Journal of functional biomaterials · 2024Review
- Synthesis of Keratin Nanoparticles Extracted from Human Hair through Hydrolysis with Concentrated Sulfuric Acid: Characterization and Cytotoxicity.Materials (Basel, Switzerland) · 2024Article
- Silver nanoparticle with potential antimicrobial and antibiofilm efficiency against multiple drug resistant, extensive drug resistant Pseudomonas aeruginosa clinical isolates.BMC microbiology · 2024Article
- Targeted Delivery of Nanoparticles to Blood Vessels for the Treatment of Atherosclerosis.Biomedicines · 2024Review
84 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, nanoparticles (NPs) have increasingly found practical applications in technology, research and medicine. The small particle size coupled to their unique chemical and physical properties is thought to underlie their exploitable biomedical activities. Here, we review current toxicity studies of NPs with clinical potential. Mechanisms of cytotoxicity are discussed and the problem of extrapolating knowledge gained from cell-based studies into a human scenario is highlighted. The so-called 'proof-of-principle' approach, whereby ultra-high NP concentrations are used to ensure cytotoxicity, is evaluated on the basis of two considerations; firstly, from a scientific perspective, the concentrations used are in no way related to the actual doses required which, in many instances, discourages further vital investigations. Secondly, these inaccurate results cast doubt on the science of nanomedicine and thus, quite dangerously, encourage unnecessary alarm in the public. In this context, the discrepancies between in vitro and in vivo results are described along with the need for a unifying protocol for reliable and realistic toxicity reports.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.